NCT00133887View on ClinicalTrials.gov

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

March 31, 2011

Study Completion Date

May 31, 2014

Conditions
Skin CancerKidney Transplantation
Interventions
DRUG

rapamycin

3 to 5 mg/day

DRUG

ciclosporine

Blood residual level \< or = to 125 ng/ml

DRUG

tacrolimus

Blood residual level \< or = to 8 ng/ml

Trial Locations (1)

69003

Hôpital Edouard Herriot - Service de Dermatologie, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT00133887 - TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter